# Pulse Biosciences, Inc Common Stock (DE) (PLSE)

> Pulse Biosciences, Inc Common Stock (DE) (PLSE) trades at $44.84 (-3.28%) as of 7:30:02 PM EST on Nov 17, 2026, -5.70% over the past month. Market cap is $3.41B, with 8.3 days to cover in short interest.

Canonical: https://massive.com/quote/plse
Data as of: 2026-11-18T00:30:02.461Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$44.84** -1.52 (-3.28%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$46.00** +1.16 (+2.59%)
As of 7:30:02 PM EST on Nov 17, 2026 · After hours

## Stock performance

How Pulse Biosciences, Inc Common Stock (DE) (PLSE) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -3.28% |
| 1W | -18.65% |
| 1M | -5.70% |
| YTD | +226.58% |
| 1Y | +230.19% |
| 52-wk range | $12.56 – $58.94 |

From daily closes through Nov 17, 2026.

## Key statistics

Today's trading snapshot for PLSE: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $43.14 – $46.41 |
| Open | $46.16 |
| Prev close | $46.36 |
| Volume | 629.04K |
| Market cap | $3.41B |
| Shares out | 73.55M |

## Valuation and profitability ratios

Valuation and profitability ratios for Pulse Biosciences, Inc Common Stock (DE): P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 2282.28 |
| P/B | 18.57 |
| P/FCF | — |
| ROE | -45.6% |
| ROA | -41.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 16, 2026

## Insider trading

[Pulse Biosciences, Inc Common Stock (DE) (PLSE) insider trading](https://massive.com/quote/plse/insider-trading.md): open-market Form 4 buys and sells by Pulse Biosciences, Inc Common Stock (DE) insiders over the last 12 months.

## 8-K filings

Material corporate events Pulse Biosciences, Inc Common Stock (DE) has disclosed to the SEC on Form 8-K.

- Nov 6, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On November 6, 2026, Pulse Biosciences, Inc. announced interim six-month results from its PRECISE-BTN clinical study. The study is evaluating the Company's nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules.”
- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Pulse Biosciences, Inc. (the "Company") announced certain financial and operational results for the fiscal quarter ended September 30, 2026.”
- Oct 14, 2026 · Partnership or collaboration
  “On October 14, 2026, Pulse Biosciences, Inc. (the "Company") announced entering into certain agreements with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates, which together form a commercial and clinical partnership between them to explore the clinical utility of the Company's proprietary nPulse Vybrance Percutaneous Electrode System.”
- Sep 15, 2026 · Deal termination
  “On September 14, 2026, the Company terminated its at-the-market offering program in accordance with the terms of its prior equity distribution agreement... As of the time of its termination, shares of Common Stock having an aggregate offering price of up to $1.0 million remained unsold under the TD Cowen Distribution Agreement.”
- Sep 15, 2026 · Business update
  “Enrollment was completed following an expansion of the Study from its original 50-patient design to 100 patients. All patients were enrolled across three U.S. clinical sites — Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine — within approximately 12 months.”

## PLSE short interest

How heavily PLSE is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.3 |
| Short interest | 2.9M |
| Avg volume | 351.72K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## PLSE news

The latest news and headlines about Pulse Biosciences, Inc Common Stock (DE) (PLSE).

- [Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue Estimates](https://www.zacks.com/stock/news/3025024/pulse-biosciences-inc-plse-reports-q3-loss-misses-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025024) · Zacks Investment Research · Nov 5, 2026 · neutral sentiment
- [Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates](https://www.zacks.com/stock/news/3021161/si-bone-sibn-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3021161) · Zacks Investment Research · Nov 2, 2026 · neutral sentiment
- [Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript](https://www.fool.com/earnings/call-transcripts/2026/05/04/pulse-biosciences-plse-q1-2025-earnings-transcript/?source=iedfolrf0000001) · The Motley Fool · May 4, 2026 · positive sentiment
- [Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday](https://www.benzinga.com/news/earnings/24/04/38016496/oxford-industries-pvh-and-3-stocks-to-watch-heading-into-monday) · Benzinga · Apr 1, 2024
- [Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session](https://www.benzinga.com/news/24/03/37595253/why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-sessio) · Benzinga · Mar 11, 2024

## About Pulse Biosciences, Inc Common Stock (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 116 |
| Listed | May 18, 2016 |

[Company website](https://www.pulsebiosciences.com)

## FAQ

### What is the Pulse Biosciences, Inc Common Stock (DE) (PLSE) stock price today?

Pulse Biosciences, Inc Common Stock (DE) (PLSE) is trading at $44.84 (-3.28% on the day) as of 7:30:02 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Pulse Biosciences, Inc Common Stock (DE)?

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a…

### What is the short interest in PLSE?

As of Oct 30, 2026, PLSE has 2.9M shares short and 8.3 days to cover.

### What exchange is PLSE listed on?

Pulse Biosciences, Inc Common Stock (DE) (PLSE) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

## Live data

Prices here are 15-minute delayed. For real-time PLSE quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PLSE`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Pulse Biosciences, Inc Common Stock (DE) (PLSE) insider trading](https://massive.com/quote/plse/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
